InvestorsHub Logo
Followers 48
Posts 11120
Boards Moderated 0
Alias Born 06/15/2014

Re: Tatsumaki post# 423416

Friday, 04/19/2024 7:53:11 AM

Friday, April 19, 2024 7:53:11 AM

Post# of 423839
Thanks for catching that and correcting the "huge". You discuss the need for separating from the glycerol in order to purify the EPA, but neglect to mention that the other reason is that it is almost impossible to significantly concentrate the EPA as long as the fatty acid is still bound to the glycerol. Good explanation on the purification.

You raise a good point about why the FDA has not gone after some of the supplement manufacturers. Of course the supplement manufacturers were selling omega-3 products long before any approved drugs came out, BUT although I am not sure, those products were confined to simply fish oil and were limited by the fact that they comprised no more than 18% EPA and 12% DHA. I remember after Lovaza was on the market that suddenly we began seeing higher concentration omega-3 products come on the supplement market. So I don't really know the timing of when supplement manufacturers started using the ethylated products - before or after FDA approval of Lovaza. But that timing might be an explanation as to why the FDA is not clamping down.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News